IN VITRO USE OF NF-kB INHIBITORS TO INDUCE THE SELECTIVE DEPLETION OF ALLOREACTIVE T-LYMPHOCYTES, DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND USES OF SAME

The invention relates to the in vitro use of NF-kB inhibitors to induce the selective depletion of alloreactive T-lymphocytes, to derivative pharmaceutical compositions and to uses of same. More specifically, the invention relates to the in vitro use of NF-kB inhibitors to induce the selective depletion of alloreactive T-lymphocytes following mixed culture. In particular, the invention relates to the in vitro use of NF-kB inhibitors, preferably proteosome inhibitors and more preferably still bortezomib inhibitors in mixed lymphocyte cultures (MLR) in order to induce the selective depletion of alloreactive T-lymphocytes and to reduce the production of Th1 cytokines. The invention also relates to pharmaceutical compositions and the therapeutic use thereof. La presente invención se refiere al uso de inhibidores del NF-kB in vitro para inducir la depleción selectiva de linfocitos T alorreactivos tras cultivo mixto. En particular la presente invención se refiere al uso in vitro de inhibidores del NF-kB, preferiblemente inhibidores de la proteosoma y más preferiblemente bortezomib, en cultivos mixtos de linfocitos (MLR) para inducir la depleción selectiva de los linfocitos T alorreactivos y disminuir la producción de citoquinas Th1. Así como a composiciones farmacéuticas y su uso en terapia.